Publications by authors named "M Guberina"
Over 40% stage-III non-small-cell lung cancer (NSCLC) patients (pts) experience 5-year survival following multimodality treatment. Nevertheless, little is known about relevant late toxicities and quality-of-life (QoL) in the further long-term follow-up. Therefore, we invited pts from our randomized phase-III trial (Eberhardt et al.
View Article and Find Full Text PDFArticle Synopsis
- - Talazoparib is a drug that makes cancer cells more sensitive to radiation, meaning it helps the radiation work better against the cancer, especially by changing how the cells fix their broken DNA.
- - By blocking another protein called Polθ, researchers found that they could make the cancer cells even more sensitive to Talazoparib, which could help in treating certain cancers.
- - The study showed that while Talazoparib worked well to enhance the effects of radiation on cancer cells, other similar drugs did not have the same effect, and normal (healthy) cells were not affected as much by the radiation.
To evaluate the prognostic value of biomarkers from peripheral blood obtained as routine laboratory assessment for overall survival in a cohort of stage III non-small cell lung cancer (NSCLC) patients treated with definitive radiochemotherapy at a high-volume cancer center. Seven blood biomarkers from 160 patients treated with definitive radiochemotherapy for stage III NSCLC were analyzed throughout the course treatment. Parameters were preselected using univariable and multivariable proportional hazards analysis and were assessed for internal validity using leave-one-out cross validation.
View Article and Find Full Text PDFPurpose: Radiation-induced scleral necrosis (RISN) is a less frequent complication of brachytherapy for uveal melanoma, and may require surgical treatment in selected cases. We aimed to identify the prognostic factors for RISN treatment.
Methods: All patients with brachytherapy for uveal melanoma treated at our institution between 01/1999 and 12/2016 who developed RISN were followed until 02/2021.
In patients with oligometastatic NSCLC, a cT3-cT4 primary tumor or an cN2/cN3 lymph node status was reported to be associated with unfavorable outcome. The aim of this study was to assess the importance of definitive or neoadjuvant thoracic radiochemotherapy for long-term outcome of these patients in order to find more appropriate treatment schedules. Analysis of the West Cancer Centre (WTZ) institutional database from 08/2016 to 08/2020 was performed.
View Article and Find Full Text PDF